Overview

Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2015-07-23
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Collaborator:
Actavis Inc.
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Paclitaxel